Evercore ISI Group analyst Umer Raffat initiates coverage on Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Outperform rating.
Arcosa Q2 Adj. EPS $0.60 Beats $0.57 Estimate, Sales $515.10M Beat $491.65M Estimate; Reaffirms FY21 Adj. EBITDA $270M-$290M
Arcosa (NYSE:ACA) reported quarterly earnings of $0.60 per share which beat the analyst consensus estimate of $0.57 by 5.26 percent. This is a 17.81 percent decrease over earnings of $0.73 per share from the same period
